ClinicalTrials.gg
CompletedNCT01590446Updated Jun 11, 2012

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

A Phase 1 interventional study of BMN 111 and Normal Saline in Achondroplasia, sponsored by BioMarin Pharmaceutical. Completed at 1 site in United States. Open to male participants aged 22 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-11.

Sponsored by BioMarin Pharmaceutical · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
22 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Achondroplasia by BioMarin Pharmaceutical — 2 open to participants now, 6 under way, 2 of them phase 3. Achondroplasia · BioMarin Pharmaceutical.

Planned enrollment
5th of 10
74 · median 74
Started
2012
with 1 other
Phase 1
2 of 14
none open now
Registered
1st of 14
by date

Among the 14 studies in Achondroplasia by BioMarin Pharmaceutical, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2012, is one of 2 in phase 1, and was the 1st registered.

Achondroplasia

47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.

Browse Achondroplasia studies →

Open to participants now

2 of the 14 studies in Achondroplasia by BioMarin Pharmaceutical are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: 22 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Achondroplasia by BioMarin Pharmaceutical, or all of them as a file.
02

Study summary

The purpose of this study is to measure how much of the study drug gets into the blood- stream and how long it takes the body to get rid of it when given as a single dose. Information about any side effects that may occur will also be collected.

03

Conditions studied

  • Achondroplasia

Browse trials for

Keywords

  • Achondroplasia
04

Who can participate

Ages eligible
22 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is willing and able to provide written, signed (legally authorized representative) after the nature of the study has been explained and prior to performance of any research-related procedure.
  • Is a male 22 to 45 years of age, inclusive
  • Has a body weight between 63 and 100 kg, inclusive
  • Has a (BMI) between 18 and 32 kg/m2, inclusive
  • Is able and willing to abstain from nicotine, alcohol, methylxanthine-containing beverages or food (e.g., coffee, tea, colas, chocolate, energy drinks), poppy seeds, and grapefruit juice for 48 hours prior to admission and for the duration of the study
  • Is in good health generally, as determined by medical history, physical examination, clinical laboratory evaluations, and 12-lead (ECG) at Screening
  • Is willing and able to perform all study procedures as physically possible
  • If sexually active, is willing to use a condom during sexual intercourse with female partners and to have their female partners use an additional effective means of (e.g., intrauterine device, coil, diaphragm plus spermicide, oral contraceptive) or to abstain from sexual intercourse if female partner is not surgically sterile by tubal occlusion (ligation or occluding device) or from time of initial admission to the research facility until their last study visit

Exclusion criteria

Exclusion Criteria:

  • Baseline systolic blood pressure \< 100 mmHg
  • Subjects with spontaneous orthostatic hypotension, including a systolic decline of > 20 or diastolic change of > 10 mmHg or heart rate increase of > 30 bpm
  • Has renal insufficiency as determined by \< 65 mL/min/1.73m2 using the revised calculation: (140 - age [y])
  • body weight [kg] / 72 serum creatinine [mg/dL]
  • Has anemia ( \< 12.5 gm/dL)
  • Has history of cardiac or vascular disease, including the following: Congenital heart disease; Hypertension or hypotension; Cerebrovascular disease; aortic insufficiency; atrial or ventricular arrhythmias; Cardiac valvular heart disease; Hypertrophic cardiomyopathy or other cardiomyopathy
  • Has a Screening showing any of the following: Resting heart rate \< 45 or > 100 bpm; PR interval > 210 msec; P wave duration > 120 msec; QRS interval \< 70 or > 120 msec; Corrected > 440 msec; QRS axis outside the range of -30 + 100 degrees; Right or left atrial enlargement or ventricular hypertrophy; Second- or third-degree atrioventricular block
  • Heart block or intraventricular conduction defect
  • Has diabetes mellitus Type I or Type II
  • Is being treated with angiotensin-converting enzyme inhibitors, antihypertensive medications, diuretics, calcium-channel blockers, beta-blockers, cardiac glycosides, systemic anticholinergic agents, or drugs that may impair or enhance compensatory tachycardia
  • Is being treated with growth hormone, insulin-like growth factor 1 (IGF-1), or anabolic steroids.
  • Has any acute illness associated with volume dehydration (e.g., nausea/vomiting/diarrhea).
  • Uses of any prescription medications, over-the-counter medications, or nutritional supplements within 10 days prior to dosing.
  • Uses any other product or investigational medical device within 90 days prior to screening or requires any investigational agent prior to completion of all scheduled study assessments.
  • Consumes at least 14 units/week of alcohol (1 unit approximates 360 mL beer, 100 mL wine, or 35 mL spirits) or has significant history of alcoholism or drug/chemical abuse as determined by the Investigator.
  • Has donated > 50 mL of blood or plasma within 60 days prior to study treatment administration.
  • Has a positive urine drug screen or alcohol breath test result during Screening or upon admission to the research facility.
  • Has used nicotine or tobacco-containing products (snuff, chewing tobacco, cigarettes,cigars, pipes, and nicotine replacements) within 90 days of the first dose of study treatment as confirmed by urine cotinine screen.
  • Has a positive cotinine test result during Screening or upon admission to the research facility.
  • Has a history of any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, hematological, or other major disorders as determined by the Investigator.
  • Has had a clinically significant illness within 4 weeks of administration of the first dose of study treatment as determined by the Investigator.
  • Is being treated with a concomitant medication that prolongs the QT/QTc interval within 7 days or 3 half-lives, whichever is longer, prior to the Screening Visit.
  • Has or ALT greater than 3xULN or total greater than 2xULN.
  • Has known to BMN 111 or its .
  • Has partner planning to become pregnant at any time during the study.
  • Has any condition that, in the view of the Investigator, places the subject at high risk of poor treatment compliance or of not completing the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
74 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Drug: Normal Saline

  • Active comparator
    BMN 111

    Drug: BMN 111

Interventions

  • SC injection, Part 1 single dose and Part 2 multiple dose.

    Also known as: Modified C-Natriuretic Peptide, ProCNP38

  • DrugNormal Saline

    SC injection, Part 1 single dose and Part 2 multiple dose

06

What researchers measure

Primary outcomes

  1. Safety based on vitals signs

    Time frame: Daily throughout the study Assessed for approximately 8 days following each single dose in Part 1, and for approximately 24 days following each daily dose in Part 2

  2. Safety based on adverse events

    Time frame: Daily throughout the study Assessed for approximately 8 days following each single dose in Part 1, and for approximately 24 days following each daily dose in Part 2

Secondary outcomes

  1. Pharmacokinetics

    Time frame: Daily on dosing days Assessed during Part 1 for approximately 10 days and during Part 2 for approximately 24 days

  2. Safety based on cardiovascular effects

    Time frame: Daily throughout the study Assessed for approximately 8 days following each single dose in Part 1, and for approximately 24 days following each daily dose in Part 2

07

Study locations

1 site
  • Covance CRU Inc.
    Evansville, Indiana 47710, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2012
First posted
May 3, 2012
Start
Feb 2012
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Last update
Jun 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01590446
Responsible party
Sponsor
First posted
May 3, 2012
Start date
Feb 2012
Primary completion
Jun 2012
Completion
Jun 2012
Last update
Jun 11, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vosoritide

Start the discussion